INTERMATION DISCLOSURE CITATION ATTY. DOCKET NO. PC27721 SERIAL NO. 10/706,555 Use sere a sheets if necessary) **APPLICANT** Mickelson, J. -1614 1624 FILING DATE November 12, 2003 **GROUP** U.S. PATENT DOCUMENTS EXAMINER DOCUMENT NUMBER SUBCLASS FILING DATE NAME CLASS INITIAL ZT 07/03 1) 6 5 9 7 9 Hamanaka et al. 514 183 2) 6 0 4 2 0 03/00 3 6 348 Chen et al. 514 ZT 3) 5 8 7 2 1 03/97 3 6 Anthony et al. 514 341 21 4) 5 8 8 0 0 04/97 Anthony, Neville J. 514 333 21 5 8 8 03/97 Anthony, Neville J. 277 **FOREIGN PATENT DOCUMENTS** DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO 37 6) 0 7 7 10/00 9 0 9 **EPO A61K** A61K Z(7) 9 7 9 03/97 wo 3 0 C08G C09D 27 8) 9 8 9 12/97 WO **A61K** C07D 不 9) 01/97 3 6 8 WO C07D A61K 21 10) 0 6 0 08/01 wo 1 0 C07D 24 11) 0 0 3 12/02 1 8 WO C07D A61K 12) 9 04/97 wo **C07D** A61K OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) 13) J. Rivier et al., Proc. Natl. Acad. Sci (USA) 80:4851 (1983) 31 14) W. Vale et al., Science 213:1394 (1981) Zτ 15) W. Vale et al., Rec. Prog. Horm. Res. 39:245 (1983); F. Koob, Persp. Behav. Med. 2:39 (1985) 4 16) E.B. De Souza et al., J. Neurosci. 5:3189 (1985)]. 27 17) J.E. Blatock, Physiological Reviews 69:1 (1989) **:2**r J.E. Morley, Life Sci. 41:527 (1987) 18) OT 19) E.B. De Souze, Hosp. Practice 23:59 (1988) The Merck Manual of Diagnosis and Therapy, 16 'h edition (1992) 20) 21) C.B. Nemeroff et al., Science 220:1342 (1984) C.M. Banki et al., Ain. J. Psychiatry 144:873 (1987)

EXAMINER

R.D. France et el., Biol. Psychiatry 23:86 (1988)

17 NOVEMBER 2005 DATE

INF	ORM	ATIO	ON PISCLOSUBE CITATION	ATTY. DOCKET NO. PC27721	SERIAL NO.	10/706,555		
			eral sheets if necessary)	APPLICANT Mickelson, J.	102111110.	10/100,000		
	1000 0041		AFR 1 6 2004 H	FILING DATE November 12, 2003	GROUP	1614-1624		
				TIENO DATE NOVEMBER 12, 2003	TOROUT	1014		
	24)	<u> </u>	Mayrato et al., Bigth sychiatry 25:355 (1989)					
	25)		C.B. Nemeroff et al., Arch. Gon. Reychiatry 45:577 (1988)					
	26)		P.W. Gold et al., Anz. J. Psychiatry 141:619 (1984)					
	27)		F. Holsboer et al., Psycheneuroendocrinology 9:147 (1984);					
	28)							
;	29)		R.M. Sapelsky, Arch. Gön. Psychiatry 46:1047 (1089)					
	30)		Grigoriadis et al., Neuropsychophermacelogy 2:53 (1989)					
	31)	D. R. Britton et al., Life Sci. 31:363 (1982)						
25	32)		C.W. Berndge and A.J. Dunn Regid. Peptides 16:83 (1986)					
2	33)							
27	34)		C.W. Berridge and A.J. Dunn Horm. Behav. 21:393 (1987) DVNN etal Brain Research Reviews 15:71 (1990)					
	35)		K.T. Britton et al., Psychopharmacolo		· · · · · · · · · · · · · · · · · · ·			
2	36)		K.T. Britton et al., Psychopharmacology 94:306 (1988)					
21	37)		N.R. Swerdlow et al., Psychopharmacology 88:147 (1986)					
25	38)		G.F. Koob and K.T. Britton, In: Corticotropin-Releasing Factor: Besic and Clinical Studies of a 15 Neuropeptide, E.B. De Souza and C.B. Nemeroff eds., CRC Press p.221 (1990)					
	39)		Design of Prodruge, H. Bundgaard, ea., Elsevier, 1985					
ZT	40)		A Textbook of Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard, ea. Chapter 5 "Design and Applications of Prodrugs" p.1 13-191, 1991					
	41)		Advanced Drug Delivery Reviews, H.	Bundgard, 8, p.1-38, 1992—				
24	42)		Journal of Pharmaceutical Sciences, 77, p. 285, 30 1988					
21.	43)		Chem. Pharm. Bull., N. Kakeya et al, 32, p. 692, 1984					
	44)		Pro-drugs as Novel Delivery System Carriers in Drug Design, Edward B. R.	s, T. Higuchi and V. Stella, Vol. 14 of the A.C.S. sche, ea., American Pharmaceutical Association and	Symposium Series, Peruamon Press, 10	and Bioreversible		
24	45)		G. Battaglia et al., Synapse 1:572 (19	37)				
2	46)		J.A. Miller Tetrahedron Lett. 1998,39,7	275.				
27	47)		S. L Buchwald, J. Org. Chem. 2000, 1	158.	•			
25	48)		Brockman et al., Methods in Enzymology, K Widder et al., Ed., Academic Press 42, p.309 (1985)					

14 NOVEMBER 2005

INFORMATION DISCLOSURE CITATION	ATTY, DOCKET NO. PC27721	SERIAL NO.	10/706,555				
(Use seem all sheets if necessary)	APPLICANT Mickelson, J.						
Cital	FILING DATE November 12, 2003	GROUP	1614 1624				
AFR : 6 ZLAN A							
EXAMINER DATE CONSIDERED 14 NOVEMBER 2005							
EXAMINER: Initial if reference considered, whether or not citation is in conformed communication to applicant.	ormance with MPEP 609; Orew line through citation if not in conformance	e and not considered. Inc	dude copy of this form with				

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE